Srf1 Is a Novel Regulator of Phospholipase D Activity and Is Essential to Buffer the Toxic Effects of C16:0 Platelet Activating Factor
During Alzheimer's Disease, sustained exposure to amyloid-β42 oligomers perturbs metabolism of ether-linked glycerophospholipids defined by a saturated 16 carbon chain at the sn-1 position. The intraneuronal accumulation of 1-O-hexadecyl-2-acetyl-sn-glycerophosphocholine (C16:0 PAF), but not its immediate precursor 1-O-hexadecyl-sn-glycerophosphocholine (C16:0 lyso-PAF), participates in signaling tau hyperphosphorylation and compromises neuronal viability. As C16:0 PAF is a naturally occurring lipid involved in cellular signaling, it is likely that mechanisms exist to protect cells against its toxic effects. Here, we utilized a chemical genomic approach to identify key processes specific for regulating the sensitivity of Saccharomyces cerevisiae to alkyacylglycerophosphocholines elevated in Alzheimer's Disease. We identified ten deletion mutants that were hypersensitive to C16:0 PAF and five deletion mutants that were hypersensitive to C16:0 lyso-PAF. Deletion of YDL133w, a previously uncharacterized gene which we have renamed SRF1 (Spo14 Regulatory Factor 1), resulted in the greatest differential sensitivity to C16:0 PAF over C16:0 lyso-PAF. We demonstrate that Srf1 physically interacts with Spo14, yeast phospholipase D (PLD), and is essential for PLD catalytic activity in mitotic cells. Though C16:0 PAF treatment does not impact hydrolysis of phosphatidylcholine in yeast, C16:0 PAF does promote delocalization of GFP-Spo14 and phosphatidic acid from the cell periphery. Furthermore, we demonstrate that, similar to yeast cells, PLD activity is required to protect mammalian neural cells from C16:0 PAF. Together, these findings implicate PLD as a potential neuroprotective target capable of ameliorating disruptions in lipid metabolism in response to accumulating oligomeric amyloid-β42.
Vyšlo v časopise:
Srf1 Is a Novel Regulator of Phospholipase D Activity and Is Essential to Buffer the Toxic Effects of C16:0 Platelet Activating Factor. PLoS Genet 7(2): e32767. doi:10.1371/journal.pgen.1001299
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pgen.1001299
Souhrn
During Alzheimer's Disease, sustained exposure to amyloid-β42 oligomers perturbs metabolism of ether-linked glycerophospholipids defined by a saturated 16 carbon chain at the sn-1 position. The intraneuronal accumulation of 1-O-hexadecyl-2-acetyl-sn-glycerophosphocholine (C16:0 PAF), but not its immediate precursor 1-O-hexadecyl-sn-glycerophosphocholine (C16:0 lyso-PAF), participates in signaling tau hyperphosphorylation and compromises neuronal viability. As C16:0 PAF is a naturally occurring lipid involved in cellular signaling, it is likely that mechanisms exist to protect cells against its toxic effects. Here, we utilized a chemical genomic approach to identify key processes specific for regulating the sensitivity of Saccharomyces cerevisiae to alkyacylglycerophosphocholines elevated in Alzheimer's Disease. We identified ten deletion mutants that were hypersensitive to C16:0 PAF and five deletion mutants that were hypersensitive to C16:0 lyso-PAF. Deletion of YDL133w, a previously uncharacterized gene which we have renamed SRF1 (Spo14 Regulatory Factor 1), resulted in the greatest differential sensitivity to C16:0 PAF over C16:0 lyso-PAF. We demonstrate that Srf1 physically interacts with Spo14, yeast phospholipase D (PLD), and is essential for PLD catalytic activity in mitotic cells. Though C16:0 PAF treatment does not impact hydrolysis of phosphatidylcholine in yeast, C16:0 PAF does promote delocalization of GFP-Spo14 and phosphatidic acid from the cell periphery. Furthermore, we demonstrate that, similar to yeast cells, PLD activity is required to protect mammalian neural cells from C16:0 PAF. Together, these findings implicate PLD as a potential neuroprotective target capable of ameliorating disruptions in lipid metabolism in response to accumulating oligomeric amyloid-β42.
Zdroje
1. RyanSD
WhiteheadSN
SwayneLA
MoffatTC
HouW
2009 Amyloid-{beta}42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism. Proc Natl Acad Sci U S A 106 20936 20941
2. Sanchez-MejiaRO
NewmanJW
TohS
YuGQ
ZhouY
2008 Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11 1311 1318
3. KleinJ
2000 Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm 107 1027 1063
4. SweetRA
PanchalingamK
PettegrewJW
McClureRJ
HamiltonRL
2002 Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol Aging 23 547 553
5. KriemB
SponneI
FifreA
Malaplate-ArmandC
Lozac'h-PillotK
2005 Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide. FASEB J 19 85 87
6. KitaY
OhtoT
UozumiN
ShimizuT
2006 Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. Biochim Biophys Acta 1761 1317 1322
7. CalonF
LimGP
YangF
MoriharaT
TeterB
2004 Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43 633 645
8. BateC
TayebiM
WilliamsA
2010 Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration. Mol Neurodegener 5 13
9. LiJ
HuJ
ShaoB
ZhouW
CuiY
2009 Protection of PMS777, a new AChE inhibitor with PAF antagonism, against amyloid-beta-induced neuronal apoptosis and neuroinflammation. Cell Mol Neurobiol 29 589 595
10. RyanSD
HarrisCS
MoF
LeeH
HouST
2007 Platelet activating factor-induced neuronal apoptosis is initiated independently of its G-protein coupled PAF receptor and is inhibited by the benzoate orsellinic acid. J Neurochem 103 88 97
11. HoonS
St OngeRP
GiaeverG
NislowC
2008 Yeast chemical genomics and drug discovery: an update. Trends Pharmacol Sci 29 499 504
12. KhuranaV
LindquistS
2010 Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast? Nat Rev Neurosci 11 436 449
13. NielsenJ
2009 Systems biology of lipid metabolism: from yeast to human. FEBS Lett 583 3905 3913
14. NakayamaR
KumagaiH
SaitoK
1994 Evidence for production of platelet-activating factor by yeast Saccharomyces cerevisiae cells. Biochim Biophys Acta 1199 137 142
15. NakayamaR
UdagawaH
KumagaiH
1997 Changes in PAF (platelet-activating factor) production during cell cycle of yeast Saccharomyces cerevisiae. Biosci Biotechnol Biochem 61 631 635
16. NakayamaR
YunC
TamakiH
SaitoK
KumagaiH
1996 Physiological action of PAF in yeast Saccharomyces cerevisiae. Adv Exp Med Biol 416 45 50
17. ZarembergV
McMasterCR
2002 Differential partitioning of lipids metabolized by separate yeast glycerol-3-phosphate acyltransferases reveals that phospholipase D generation of phosphatidic acid mediates sensitivity to choline-containing lysolipids and drugs. J Biol Chem 277 39035 39044
18. ZarembergV
GajateC
CacharroLM
MollinedoF
McMasterCR
2005 Cytotoxicity of an anti-cancer lysophospholipid through selective modification of lipid raft composition. J Biol Chem 280 38047 38058
19. BrewerC
BoninF
BullockP
NaultMC
MorinJ
2002 Platelet activating factor-induced apoptosis is inhibited by ectopic expression of the platelet activating factor G-protein coupled receptor. J Neurochem 82 1502 1511
20. GavinAC
AloyP
GrandiP
KrauseR
BoescheM
2006 Proteome survey reveals modularity of the yeast cell machinery. Nature 440 631 636
21. KroganNJ
CagneyG
YuH
ZhongG
GuoX
2006 Global landscape of protein complexes in the yeast Saccharomyces cerevisiae. Nature 440 637 643
22. LambertJP
MitchellL
RudnerA
BaetzK
FigeysD
2009 A novel proteomics approach for the discovery of chromatin-associated protein networks. Mol Cell Proteomics 8 870 882
23. LambertJP
BaetzK
FigeysD
2010 Of proteins and DNA—proteomic role in the field of chromatin research. Mol Biosyst 6 30 37
24. RudgeSA
MorrisAJ
EngebrechtJ
1998 Relocalization of phospholipase D activity mediates membrane formation during meiosis. J Cell Biol 140 81 90
25. HonigbergSM
ConicellaC
EspositioRE
1992 Commitment to meiosis in Saccharomyces cerevisiae: involvement of the SPO14 gene. Genetics 130 703 716
26. ConnollyJE
EngebrechtJ
2006 The Arf-GTPase-activating protein Gcs1p is essential for sporulation and regulates the phospholipase D Spo14p. Eukaryot Cell 5 112 124
27. MarstonAL
ThamWH
ShahH
AmonA
2004 A genome-wide screen identifies genes required for centromeric cohesion. Science 303 1367 1370
28. EllaKM
DolanJW
MeierKE
1995 Characterization of a regulated form of phospholipase D in the yeast Saccharomyces cerevisiae. Biochem J 307 799 805
29. EllaKM
MeierGP
BradshawCD
HuffmanKM
SpiveyEC
1994 A fluorescent assay for agonist-activated phospholipase D in mammalian cell extracts. Anal Biochem 218 136 142
30. RiedelCG
MazzaM
MaierP
KornerR
KnopM
2005 Differential requirement for phospholipase D/Spo14 and its novel interactor Sma1 for regulation of exocytotic vesicle fusion in yeast meiosis. J Biol Chem 280 37846 37852
31. LoewenCJ
GasparML
JeschSA
DelonC
KtistakisNT
2004 Phospholipid metabolism regulated by a transcription factor sensing phosphatidic acid. Science 304 1644 1647
32. CaiD
NetzerWJ
ZhongM
LinY
DuG
2006 Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation. Proc Natl Acad Sci U S A 103 1941 1946
33. CaiD
ZhongM
WangR
NetzerWJ
ShieldsD
2006 Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc Natl Acad Sci U S A 103 1936 1940
34. ScottSA
SelvyPE
BuckJR
ChoHP
CriswellTL
2009 Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol 5 108 117
35. RyanSD
HarrisCS
CarswellCL
BaenzigerJE
BennettSA
2008 Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. J Lipid Res 49 2250 2258
36. FairnGD
CurwinAJ
StefanCJ
McMasterCR
2007 The oxysterol binding protein Kes1p regulates Golgi apparatus phosphatidylinositol-4-phosphate function. Proc Natl Acad Sci U S A 104 15352 15357
37. RoseK
RudgeSA
FrohmanMA
MorrisAJ
EngebrechtJ
1995 Phospholipase D signaling is essential for meiosis. Proc Natl Acad Sci U S A 92 12151 12155
38. RudgeSA
CavenaghMM
KamathR
SciorraVA
MorrisAJ
1998 ADP-Ribosylation factors do not activate yeast phospholipase Ds but are required for sporulation. Mol Biol Cell 9 2025 2036
39. MendonsaR
EngebrechtJ
2009 Phospholipase D function in Saccharomyces cerevisiae. Biochim Biophys Acta 1791 970 974
40. PaiJK
SiegelMI
EganRW
BillahMM
1988 Phospholipase D catalyzes phospholipid metabolism in chemotactic peptide-stimulated HL-60 granulocytes. J Biol Chem 263 12472 12477
41. KiharaY
IshiiS
KitaY
TodaA
ShimadaA
2005 Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. J Exp Med 202 853 863
42. WaltherTC
BricknerJH
AguilarPS
BernalesS
PantojaC
2006 Eisosomes mark static sites of endocytosis. Nature 439 998 1003
43. AguilarPS
FrohlichF
RehmanM
ShalesM
UlitskyI
2010 A plasma-membrane E-MAP reveals links of the eisosome with sphingolipid metabolism and endosomal trafficking. Nat Struct Mol Biol
44. OliveiraTG
Di PaoloG
2010 Phospholipase D in brain function and Alzheimer's disease. Biochim Biophys Acta 1801 799 805
45. LongtineMS
McKenzieA3rd
DemariniDJ
ShahNG
WachA
1998 Additional modules for versatile and economical PCR-based gene deletion and modification in Saccharomyces cerevisiae. Yeast 14 953 961
46. RigautG
ShevchenkoA
RutzB
WilmM
MannM
1999 A generic protein purification method for protein complex characterization and proteome exploration. Nat Biotechnol 17 1030 1032
47. AbelsonJN
SimonML
GutherieC
FinkGR
2004 Guide to Yeast Genetics and Molecular Biology. California Elsevier Academic Press
48. MemarianN
JessulatM
AlirezaieJ
Mir-RashedN
XuJ
2007 Colony size measurement of the yeast gene deletion strains for functional genomics. BMC Bioinformatics 8 117
49. ParsonsAB
BrostRL
DingH
LiZ
ZhangC
2004 Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat Biotechnol 22 62 69
50. ParsonsAB
LopezA
GivoniIE
WilliamsDE
GrayCA
2006 Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126 611 625
51. PinheiroJC
BatesDM
2000 Mixed-Effects Models in S and S-Plus; Chambers J, editor. New York Springer
52. PinheiroJC
BatesDM
DebRoyS
SarkarD
2008 nlme: Linear and Nonlinear Mixed Effects Models. R package 3.1-90 ed ed
53. Team RDC 2008 R: A Language and Environment for Statistical Computing. Vienna, Austria R Foundation for Statistical Computing
54. SikorskiRS
HieterP
1989 A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122 19 27
Štítky
Genetika Reprodukčná medicínaČlánok vyšiel v časopise
PLOS Genetics
2011 Číslo 2
- Gynekologové a odborníci na reprodukční medicínu se sejdou na prvním virtuálním summitu
- Je „freeze-all“ pro všechny? Odborníci na fertilitu diskutovali na virtuálním summitu
Najčítanejšie v tomto čísle
- Meta-Analysis of Genome-Wide Association Studies in Celiac Disease and Rheumatoid Arthritis Identifies Fourteen Non-HLA Shared Loci
- MiRNA Control of Vegetative Phase Change in Trees
- The Cardiac Transcription Network Modulated by Gata4, Mef2a, Nkx2.5, Srf, Histone Modifications, and MicroRNAs
- Break to Make a Connection